Paradigm Spine to Fund Trailblazing Genetic Research to Introduce the First Diagnostic Test Able to Predict Idiopathic Scoliosis

NEW YORK, June 5 /PRNewswire/ -- A newly developed diagnostic test that
promises to radically change the treatment of adolescent idiopathic
scoliosis is to be evaluated in trials funded by Paradigm Spine, LLC.
('Paradigm'). The trials will be conducted at Montreal's renowned
Sainte-Justine University Hospital Center ('Ste.-Justine'), known globally
for its research into scoliosis and other neuro-musculoskeletal diseases.
Paradigm focuses on development of less invasive and tissue-sparing
treatments for spinal diseases.
Marc R. Viscogliosi, Paradigm's Chief Executive, told an audience at
Ste.- Justine: "I believe we may be on the brink of discovering the secret
to the causes of scoliosis that until now were so complex that children
were diagnosed purely on visual examination -- long after the disease had
taken hold."
Paradigm signed an agreement with Ste.-Justine to provide cash and
various other resources through 2008 to complete trials of a blood test
devised by Dr. Alain Moreau, director of Ste. Justine's Bone Molecular
Genetics and Skeletal Malformations Laboratories.
For Dr. Moreau, successful trials will validate work begun in 2001
under the auspices of the Yves Cotrel Foundation, in France, and continued
at Ste.- Justine. Idiopathic scoliosis afflicts more than one million
adolescents (10- 16 years old), in North America of which 13% may undergo
therapeutic bracing treatment or some form of surgical correction.
To date the test has proven effective in identifying the presence of a
genetic marker in animals and post-scoliotic patients. The proposed
clinical trials are intended to demonstrate the effectiveness of the test
using blood samples from early-stage scoliosis patients and an unaffected
control group.
"Dr. Moreau's trailblazing work suggests a major scientific
breakthrough that would change the way adolescent scoliosis is diagnosed
and treated. We have followed his work for some time and are delighted to
provide support for this critical trial," Mr. Viscogliosi said.
In its agreement with Ste.-Justine, Paradigm will receive the exclusive
worldwide license to commercialize, manufacture, distribute, or sub-license
any device, genetic tests, therapeutic agents, or any future technology
derived from Dr. Moreau's scoliosis research.
Dr. Moreau said: "Scoliosis is a gradual, debilitating condition, both
physically and psychologically. Treatment is difficult because, until the
curvature of the spine exceeds a 'normal' angle, indicating scoliotic
progression, very little can be done to correct it. We hope that this new
test will provide the answer so that timely and less invasive measures can
be adopted to effectively treat the disease."
According to Dr. Moreau, the results of his research, that began in
2001, made him optimistic that the progression of scoliosis would be
predictable in infants using well understood genetic markers.
"The possibility of applying the results to future genetically based
therapies is also very real and obviously quite exciting," Dr. Moreau
added.
Paradigm has followed closely Dr. Moreau's research and that of his
colleagues for more than five years through its relationship with his
colleague at Ste.-Justine, Dr. Charles Rivard. Dr. Rivard is the inventor
of Orthobiom, an experimental non-fusion treatment for late stage
scoliosis, also being developed by Paradigm.
Mr. Viscogliosi added: "Underwriting Dr. Moreau's research will, we
hope, be life changing not only for affected children, but also for my
family. Having spent most of our working lives in the field of
musculoskeletal research and development, my brothers and I are now
fortunate to be able to provide significant funds for advancing
life-changing treatments and technologies.
During the past decade the Viscogliosi brothers have supported
orthopedic and musculoskeletal development work at three university
hospital spine units in France and at the New York Hospital for Special
Surgery, the NYU Hospital for Joint Diseases, and the American Spinal
Injury Association. The Viscogliosi brothers also founded the Spine
Arthroplasty Society and several other spine-related organizations.
The clinical trials for Dr. Moreau's new diagnostic test will include
panels of children attending the three Ste.-Justine scoliosis clinics, as
well as a control group of children with no symptoms of the disease. The
results of the trials are expected to be available in early 2008.
About Paradigm Spine, LLC
Paradigm Spine is a company focused on providing indication specific
posterior non-fusion solutions for orthopedic spine surgeons and
neurosurgeons focused on treating spinal conditions and diseases.
The company's founding philosophy is "Surgeon Centric, Indication
Specific, Data Driven," and focuses on providing the best clinical outcomes
for patients suffering from chronic back pain.
The company is concentrating on building a multi-product non-fusion
portfolio. One product is the coflex(TM) device, a posterior non-fusion
interspinous dynamically-functional implant, which has a long clinical
history of over a decade of use and has been implanted in more than 10,000
patients suffering from low back pain and lumbar spinal stenosis.
Paradigm Spine's second core platform is the Orthobiom(TM) technology,
also in development for over a decade. The Orthobiom(TM) technology treats
adolescent idiopathic scoliosis, a condition in children which causes
severe curvature of the spine and which is usually surgically treated with
a spinal fusion procedure. The Orthobiom(TM) system is a non-fusion
alternative designed to preserve the motion and growth of the child's
spine. It is a revolutionary product that could potentially help the lives
of tens of thousands of children each year.
Paradigm Spine, LLC was founded in 2004 by Viscogliosi Brothers, LLC
('VB') and, in May 2006, completed a Series C private funding of $14
million. Established by Marc R. Viscogliosi, John J. Viscogliosi and
Anthony G. Viscogliosi in New York City, in 1999, VB is the first venture
capital/private equity and merchant banking firm dedicated to the $26.4
billion musculoskeletal-orthopedics device sector of the health care
industry.
Today, VB is a leading independent firm, with a mission to create,
build and finance companies founded on innovations developed by surgeons
and uniquely focused on "life-changing" musculoskeletal/orthopedic
technologies. VB has worldwide surgeon, industry and trade relationships
and significant financial expertise in the musculoskeletal/orthopedic
sector.
For more, visit: http://www.paradigmspine.com
About CHU Sainte-Justine and its Research Centre
The Sainte-Justine University Hospital Centre is the largest
mother-child centre in Canada. It encompasses 450 beds, admits 19,000
people annually and welcomes 260,000 patients at its Outpatients Clinic.
With over 4,000 employees, it is one of the four largest pediatric centres
on the American continent. Its research centre employs 163 researchers and
320 postdoctoral graduates and training students. Important clinical and
fundamental research activities are conducted there to better understand
health problems of the mother, the foetus, the child and teenager, to
optimize diagnostics and therapeutic solutions and offer genuine prevention
programs. Affiliated with the Universite de Montreal, the Sainte-Justine
UHC is by far Quebec's largest pediatric training centre, and a leader in
Canada. Each year, it welcomes about 4,000 students. The global reach of
the Sainte-Justine UHC and its research centre is considerable. The
Sainte-Justine UHC will be celebrating its 100th anniversary in 2007.
For more, visit: http://www.chu-sainte-justine.org/

SOURCE Paradigm Spine, LLC

NEW YORK, June 5 /PRNewswire/ -- A newly developed diagnostic test that
promises to radically change the treatment of adolescent idiopathic
scoliosis is to be evaluated in trials funded by Paradigm Spine, LLC.
('Paradigm'). The trials will be conducted at Montreal's renowned
Sainte-Justine University Hospital Center ('Ste.-Justine'), known globally
for its research into scoliosis and other neuro-musculoskeletal diseases.
Paradigm focuses on development of less invasive and tissue-sparing
treatments for spinal diseases.
Marc R. Viscogliosi, Paradigm's Chief Executive, told an audience at
Ste.- Justine: "I believe we may be on the brink of discovering the secret
to the causes of scoliosis that until now were so complex that children
were diagnosed purely on visual examination -- long after the disease had
taken hold."
Paradigm signed an agreement with Ste.-Justine to provide cash and
various other resources through 2008 to complete trials of a blood test
devised by Dr. Alain Moreau, director of Ste. Justine's Bone Molecular
Genetics and Skeletal Malformations Laboratories.
For Dr. Moreau, successful trials will validate work begun in 2001
under the auspices of the Yves Cotrel Foundation, in France, and continued
at Ste.- Justine. Idiopathic scoliosis afflicts more than one million
adolescents (10- 16 years old), in North America of which 13% may undergo
therapeutic bracing treatment or some form of surgical correction.
To date the test has proven effective in identifying the presence of a
genetic marker in animals and post-scoliotic patients. The proposed
clinical trials are intended to demonstrate the effectiveness of the test
using blood samples from early-stage scoliosis patients and an unaffected
control group.
"Dr. Moreau's trailblazing work suggests a major scientific
breakthrough that would change the way adolescent scoliosis is diagnosed
and treated. We have followed his work for some time and are delighted to
provide support for this critical trial," Mr. Viscogliosi said.
In its agreement with Ste.-Justine, Paradigm will receive the exclusive
worldwide license to commercialize, manufacture, distribute, or sub-license
any device, genetic tests, therapeutic agents, or any future technology
derived from Dr. Moreau's scoliosis research.
Dr. Moreau said: "Scoliosis is a gradual, debilitating condition, both
physically and psychologically. Treatment is difficult because, until the
curvature of the spine exceeds a 'normal' angle, indicating scoliotic
progression, very little can be done to correct it. We hope that this new
test will provide the answer so that timely and less invasive measures can
be adopted to effectively treat the disease."
According to Dr. Moreau, the results of his research, that began in
2001, made him optimistic that the progression of scoliosis would be
predictable in infants using well understood genetic markers.
"The possibility of applying the results to future genetically based
therapies is also very real and obviously quite exciting," Dr. Moreau
added.
Paradigm has followed closely Dr. Moreau's research and that of his
colleagues for more than five years through its relationship with his
colleague at Ste.-Justine, Dr. Charles Rivard. Dr. Rivard is the inventor
of Orthobiom, an experimental non-fusion treatment for late stage
scoliosis, also being developed by Paradigm.
Mr. Viscogliosi added: "Underwriting Dr. Moreau's research will, we
hope, be life changing not only for affected children, but also for my
family. Having spent most of our working lives in the field of
musculoskeletal research and development, my brothers and I are now
fortunate to be able to provide significant funds for advancing
life-changing treatments and technologies.
During the past decade the Viscogliosi brothers have supported
orthopedic and musculoskeletal development work at three university
hospital spine units in France and at the New York Hospital for Special
Surgery, the NYU Hospital for Joint Diseases, and the American Spinal
Injury Association. The Viscogliosi brothers also founded the Spine
Arthroplasty Society and several other spine-related organizations.
The clinical trials for Dr. Moreau's new diagnostic test will include
panels of children attending the three Ste.-Justine scoliosis clinics, as
well as a control group of children with no symptoms of the disease. The
results of the trials are expected to be available in early 2008.
About Paradigm Spine, LLC
Paradigm Spine is a company focused on providing indication specific
posterior non-fusion solutions for orthopedic spine surgeons and
neurosurgeons focused on treating spinal conditions and diseases.
The company's founding philosophy is "Surgeon Centric, Indication
Specific, Data Driven," and focuses on providing the best clinical outcomes
for patients suffering from chronic back pain.
The company is concentrating on building a multi-product non-fusion
portfolio. One product is the coflex(TM) device, a posterior non-fusion
interspinous dynamically-functional implant, which has a long clinical
history of over a decade of use and has been implanted in more than 10,000
patients suffering from low back pain and lumbar spinal stenosis.
Paradigm Spine's second core platform is the Orthobiom(TM) technology,
also in development for over a decade. The Orthobiom(TM) technology treats
adolescent idiopathic scoliosis, a condition in children which causes
severe curvature of the spine and which is usually surgically treated with
a spinal fusion procedure. The Orthobiom(TM) system is a non-fusion
alternative designed to preserve the motion and growth of the child's
spine. It is a revolutionary product that could potentially help the lives
of tens of thousands of children each year.
Paradigm Spine, LLC was founded in 2004 by Viscogliosi Brothers, LLC
('VB') and, in May 2006, completed a Series C private funding of $14
million. Established by Marc R. Viscogliosi, John J. Viscogliosi and
Anthony G. Viscogliosi in New York City, in 1999, VB is the first venture
capital/private equity and merchant banking firm dedicated to the $26.4
billion musculoskeletal-orthopedics device sector of the health care
industry.
Today, VB is a leading independent firm, with a mission to create,
build and finance companies founded on innovations developed by surgeons
and uniquely focused on "life-changing" musculoskeletal/orthopedic
technologies. VB has worldwide surgeon, industry and trade relationships
and significant financial expertise in the musculoskeletal/orthopedic
sector.
For more, visit: http://www.paradigmspine.com
About CHU Sainte-Justine and its Research Centre
The Sainte-Justine University Hospital Centre is the largest
mother-child centre in Canada. It encompasses 450 beds, admits 19,000
people annually and welcomes 260,000 patients at its Outpatients Clinic.
With over 4,000 employees, it is one of the four largest pediatric centres
on the American continent. Its research centre employs 163 researchers and
320 postdoctoral graduates and training students. Important clinical and
fundamental research activities are conducted there to better understand
health problems of the mother, the foetus, the child and teenager, to
optimize diagnostics and therapeutic solutions and offer genuine prevention
programs. Affiliated with the Universite de Montreal, the Sainte-Justine
UHC is by far Quebec's largest pediatric training centre, and a leader in
Canada. Each year, it welcomes about 4,000 students. The global reach of
the Sainte-Justine UHC and its research centre is considerable. The
Sainte-Justine UHC will be celebrating its 100th anniversary in 2007.
For more, visit: http://www.chu-sainte-justine.org/
SOURCE Paradigm Spine, LLC